Abstract The PI3K/Akt/mTOR pathway mediates multiple myeloma (MM) cell proliferation,
survival, and development of drug resistance, underscoring the role of mTOR inhibitors such …

The malignant plasma cell of Multiple Myeloma (MM) is closely linked to dysregulated
unfolded protein response in the ER due to increased production of immunoglobulin and the …

Curative responses in the treatment of multiple myeloma (MM) are limited by the emergence
of therapeutic resistance. To address this problem, we set out to identify druggable …

Background LGH447 is a novel, specific pan-Pim kinase inhibitor in development for the
treatment of patients with multiple myeloma (MM) and other hematologic malignancies. The …

Cancer often involves the overactivation of RAS/RAF/MEK/ERK (MAPK) and PI3K-Akt-mTOR
pathways due to mutations in genes like RAS, RAF, PTEN, and PIK3CA. Various strategies …

The mitogen-activated protein kinase (MAPK) signaling pathway is frequently activated in
human cancers due to genetic alterations that can occur at multiple nodes, the most …

TPS3164 Background: Approved BRAF inhibitors (BRAFi) are inactive against RAF dimers.
Accordingly, the acquisition of BRAF dimers (eg., through drug-acquired splice variants or …

Introduction Multiple myeloma (MM) is a B cell cancer mainly characterized by proliferation
of malignant plasma cells in the bone marrow, presence of a monoclonal serum …

Despite many available effective agents for multiple myeloma (MM), the development of
drug resistance is inevitable and novel regimens are needed. BET (bromodomain and extra …

BACKGROUND Mutations in the RAS‐MAPK pathway, such as KRAS, NRAS, and BRAF,
are known as high‐risk factors associated with poor prognosis in patients with various …